Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Janssen, MD
Dynavax Technologies Corporation
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Optimal Research Alabama
Huntsville, Alabama, United States
- Optimal Research California
San Diego, California, United States
- Optimal Research Florida
Melbourne, Florida, United States
- Optimal Research Illinois
Peoria, Illinois, United States
- Optimal Research Maryland
Rockville, Maryland, United States
- Optimal Research Texas
Austin, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Aug 2022
- Primary completion
- 3 Oct 2023
- Completion
- 26 Apr 2024
- Last update posted
- 29 Jul 2025
- Registered enrollment
- 200
- Registry id
- NCT05506969
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.